Press release
Protheragen Announces Microneedle Technology Services to Accelerate Transdermal Drug Delivery Innovation
New York/US - September 29, 2026 - Protheragen has advanced its integrated microneedle technology solutions, delivering endtoend custom services including formulation development and material selection & characterization for pharmaceutical enterprises, cosmetic companies, and related industry partners. The service portfolio covers multiple mainstream microneedle formats, including coated microneedle development, dissolving microneedle, hollow microneedle, hydrogelforming microneedle, and solid microneedle, to satisfy diversified transdermal drug delivery demands for smallmolecule compounds, proteins, nucleic acids, and other active substances.
Microneedle technology [https://www.protheragen.ai/microneedle-technology-services.html] is an innovative transdermal drug delivery system that employs micronscale needles to pierce the stratum corneum and deliver therapeutic agents to targeted skin depths to join local microcirculation. By bypassing gastrointestinal digestion and firstpass metabolism, this technology improves drug bioavailability, enables localized therapy to lower systemic adversereaction risks, and supports sustained or controllable drug release through structural tuning of microneedle arrays.
Within its fullscope microneedle technology solutions, Protheragen offers specialized coated microneedle development services [https://www.protheragen.ai/coated-microneedle-development-services.html] for surfaceloaded delivery systems. Coated microneedles feature solid sharp substrates covered by drugcontaining soluble coating layers; once inserted into skin, interstitial fluid dissolves excipients in coatings, releasing payloads into target tissues. Protheragen supports multiple coating approaches, including masked dip coating, inkjet printing, immersion coating and, spray coating. Its service portfolio includes coatingformulation development, microneedle geometric design, coatingmaterial screening, process optimization, delivery performance evaluation, and safety compatibility assessment, to secure uniform drug distribution, preserved drug bioactivity, and expected release profiles.
Meanwhile, the dissolving microneedle platform [https://www.protheragen.ai/dissolving-microneedle-development-services.html] constitutes another core offering under Protheragen's service suite. Dissolving microneedles embed active pharmaceutical ingredients within biodegradable polymer matrices. After skin application, the whole needle body dissolves completely inside tissue, generating no sharp biohazard waste and enabling painfree selfadministration. Protheragen leverages PDMSmoldbased fabrication workflows, together with a broad selection of matrix materials such as carboxymethyl chitosan, PVP, PVA, and PLGA. Its dissolving microneedle services span structural design, prototyping, formulation optimization, analytical testing covering mechanical strength, dissolution kinetics, and biocompatibility, as well as regulatory document support for clients from the pharmaceutical and cosmetic sectors.
Backed by crossdisciplinary teams of scientists and engineers, Protheragen's microneedle technology services run through the whole R&D pipeline: initial concept design, prototype preparation, material characterization, formulation optimization, preclinical and clinical evaluation, manufacturing scaleup, and postcommercialization technical support. Protheragen maintains collaborative links with global pharmaceutical firms, medicaldevice manufacturers, and research institutes to keep pace with cuttingedge microneedle research progress.
About Protheragen
Protheragen provides comprehensive, tailormade drug delivery development services for various advanced delivery technologies, supporting partners to overcome technical bottlenecks in drug permeability, stability, and administration mode. Whether clients are in the pharmaceutical industry, medical research, or a related field, its team of experts is ready to support researchers' novel drug delivery development needs.
Media Contact
Company Name: Protheragen
Contact Person: Hannah Green
Email: Send Email [http://www.universalpressrelease.com/?pr=protheragen-announces-microneedle-technology-services-to-accelerate-transdermal-drug-delivery-innovation]
Country: United States
Website: https://www.protheragen.ai/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Protheragen Announces Microneedle Technology Services to Accelerate Transdermal Drug Delivery Innovation here
News-ID: 4647729 • Views: …
More Releases from Getnews
George McReynolds Founder of McReynolds & Company Interviewed on the Influential …
Image: https://authoritypresswire.com/wp-content/uploads/2026/09/Good-removebg-preview.png
TELFORD, PA - October 1, 2026 - George McReynolds discussing the longevity trap
Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-george-mcreynolds-founder-of-mcreynolds-company-discussing-the-longevity-trap/
In this episode of Influential Entrepreneurs, the host had the pleasure of speaking with George McReynolds, founder of McReynolds and Company. The conversation delved into the intriguing topics of the longevity trap and the taxes jaw, exploring how these issues can significantly impact retirement planning.
Plan for Longevity,…
VAIR Welcomes Dr. Douglas J. Rowles to Bring Expert Health Education to VAIR+ Me …
New member benefit will let players submit questions for video response sessions with a board-certified orthopedic surgeon and naturopathic doctor.
VAIR welcomes Dr. Douglas J. Rowles, a board-certified orthopedic surgeon and naturopathic doctor, as a new resource for VAIR+ members. Members can submit health and wellness questions through a dedicated form, and Dr. Rowles will address selected questions in video response sessions covering topics such as joint health, injury prevention, recovery…
"A New True to Me" Reveals What Happens When a Memoirist Questions His Own Memor …
Image: https://www.globalnewslines.com/uploads/2026/09/1790793765.jpg
United States - October 1, 2026 - David Lewis thought he knew the story of his life. He had overcome dyslexia, left a position at his grandfather's bank and helped build one of the country's early fee-only financial planning firms. Then he began writing his memoir and found that some of the stories he had told for decades did not hold up.
In A New True to Me: The Foundation…
Terry Wheeler, Founder & CEO of WE Alliance Wealth Advisors and Strategic Wealth …
Image: https://authoritypresswire.com/wp-content/uploads/2026/09/Terry_Wheeler_headshoot-removebg-preview.png
ROSEVILLE, CA - October 1, 2026 - Terry Wheeler discussing the investment blind spot
Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-terry-wheeler-founder-ceo-of-we-alliance-wealth-advisors-discussing-the-investment-blind-spot/
In this episode of Influential Entrepreneurs, Terry Wheeler, founder and CEO of WE Alliance Wealth Advisors, discusses the investment blind spot. Terry shares his journey into the investment industry, starting from his childhood love for Monopoly, which inspired his career as a financial advisor. Highlights the…
More Releases for Protheragen
Protheragen Introduces Comprehensive Drug Analysis Services for Pharmaceutical D …
Protheragen, a leading biotechnology company, provides effective Drug Analysis [https://www.protheragen.ai/drug-analysis.html] services that help pharmaceutical researchers and manufacturers. In drug research, drug analysis is useful for the safety, efficacy, and quality of drugs. With advanced technologies and scientific expertise, Protheragen's analytical solutions play an important role in drug development.
Drug Analysis includes many analytical procedures designed to evaluate various properties of pharmaceutical compounds. These analyses are important for understanding drug characteristics and…
Protheragen Launches One-stop Services for Rare Blood Diseases
Protheragen, a leading provider of life sciences research and development solutions, announces its innovative One-stop Services [https://www.protheragen.us/blood-disorders/our-services.html] platform designed to accelerate therapeutic discoveries and development across blood disease areas. This platform integrates advanced technologies with expert scientific consultation. The streamlined workflow can better address the challenges in research.
"Our integrated approach allows clients to handle the issues of drug development with heightened accuracy and operational efficiency," explains a senior scientist from…
Protheragen Unveils Revolutionary EndureCAR-T Trademark Cell Therapy Platform
Protheragen offers a variety of CAR-T cell therapy services, including personalized CAR-T cell analysis and therapy regimens based on a variety of disease models.
Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and EndureCART Trademark technology platform, Protheragen provides investigators a wide range of disease models to ensure detailed and customized treatment methods for superior therapeutic outcomes.
With the development of immunology, scientists…
Protheragen Announces GeniusAb Trademark : A Fully Human Single-Domain Antibody …
New York, United States - Protheragen has launched GeniusAb Trademark [https://www.geniusab.com/], a fully human single-domain antibody platform to produce high quality and customized antibodies for research, diagnostic and therapeutic use. This is a major breakthrough in the field of therapeutic antibodies as it is able to provide highly specific, robust, and versatile solutions to a variety of diseases.
Single-domain antibodies (sdAbs), also known as VHH antibodies or camelid antibodies, are derived…
Diving Deeper in Rare Disease Research: Protheragen Unveils Diagnostic Developme …
Protheragen announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research.
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development [https://www.protheragen.us/]. These diagnostic services are designed to support the scientific community in identifying, understanding, and ultimately treating rare diseases that affect millions…
Protheragen Announces Vaccine Development Services Targeting Infectious Diseases
Protheragen is proud to release its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases.
Protheragen is proud to release the launch of its comprehensive vaccine development solutions [https://infectious.protheragen.us/vaccine-development-services.html] tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats.
Infectious diseases are disorders caused by…
